Nav: Home

CTCA at Western First Arizona Hospital awarded Joint Commission Lung Cancer Certification

September 28, 2015

(Goodyear, Arizona - September 28, 2015) - Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, announced that it has earned The Joint Commission's Gold Seal of Approval® for Lung Cancer Certification.

The Gold Seal of Approval® is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care. CTCA® at Western is the first hospital in the Southwest and only the sixth hospital in the U.S. to receive this esteemed designation.

"Cancer Treatment Centers of America at Western Regional Medical Center has thoroughly demonstrated a high level of care for patients with lung cancer," said Wendi J. Roberts, RN, executive director, Certification Programs, The Joint Commission. "We commend CTCA at Western for becoming a leader in lung cancer care, potentially providing a higher standard of service for lung cancer patients in its community."

CTCA at Western underwent a rigorous on-site review in August. A Joint Commission expert evaluated compliance with national disease-specific care standards as well as with lung cancer-specific requirements. Clinical practice guidelines and performance measures were also assessed.

The Lung Center of Excellence at CTCA at Western is dedicated to providing state-of-the-art compassionate care to patients with lung cancer and to their families. CTCA at Western offers a multidisciplinary, interactive team approach for prevention and screening, while treating early and complex lung cancer through evidence based practice and research.

"We have consistently strived to provide the best care possible to our patients," stated Mark Kharoufeh, RN, BSN, Assistant Vice President of Oncology Patient Services, CTCA at Western. "This certification provides a third-party validation of our high-quality, consistent approach to patient care, treatment and services provided at our hospital."

Kharoufeh was the sponsor of the Lung Cancer Certification.

Physicians instrumental in the certification process also include:
  • Lanceford Chong, MD, MPH, Medical Director of Radiation Oncology, CTCA at Western
    Glen Weiss, MD, MBA, Director of Clinical Research & Medical Oncologist, CTCA at Western
    Ashish Sangal, MD, Director of Medical Education & Medical Oncologist, CTCA at Western
    Andrew Goldstein, MD, FACS, Director of Thoracic Surgery and Thoracic Surgeon, CTCA at Western
    Sharad Chandrika, MD, Pulmonologist & Intensivist at CTCA, Western

CTCA at Western adheres to the National Comprehensive Cancer Network clinical practice guidelines and has a robust clinical research program. Currently, CTCA at Western has nine active clinical trials for advanced lung cancer.

Twelve lung cancer-specific peer-reviewed manuscripts have recently been published. Additionally, CTCA at Western physicians have participated in 18 lung cancer posters and oral presentations - at both national and international conferences - including for the American Society of Clinical Oncology. Earlier this month, Dr. Weiss presented at the 16th World Conference on Lung Cancer.

Established in 2002 and awarded for a two-year period, The Joint Commission's Disease-Specific Care Certification evaluates clinical programs across the continuum of care and addresses three core areas:
  • Compliance with consensus-based national standards;
  • Effective use of evidence-based clinical practice guidelines to manage and optimize care; and
  • An organized approach to performance measurement and improvement activities.

-end-
For more information about CTCA, visit http://www.cancercenter.com, or call (800) 615-3055.

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America® (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based complementary therapies that support patients physically and emotionally, enhancing their quality of life while reducing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.

The Joint Commission

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission accredits and certifies nearly 21,000 health care organizations and programs in the United States. An independent, nonprofit organization, The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at http://www.jointcommission.org.

Cancer Treatment Centers of America

Related Lung Cancer Articles:

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
More Lung Cancer News and Lung Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...